Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174680 | 0.88 | AURKA (0.58) | AURKAAURKBMAPTTP53ABCG2 | |
| SCHEMBL174480 | 0.83 | AURKA (0.84) | AURKAAURKBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL173984 | 0.81 | AURKA (0.47) | AURKAAURKB | |
| SCHEMBL12102330 | 0.78 | JAK2 (0.39) | — | |
| SCHEMBL174904 | 0.77 | AURKA (0.50) | AURKAAURKBMAPTTP53ABCG2 | |
| SCHEMBL174971 | 0.76 | AURKA (0.49) | AURKAAURKB | |
| SCHEMBL174337 | 0.76 | AURKA (0.49) | AURKAAURKB | |
| SCHEMBL174604 | 0.75 | MAPT (0.68) | MAPTTP53KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL163563 | 0.74 | IGFBP3 (0.43) | AURKAAURKBTP53NPC1RAB9A | |
| SCHEMBL174917 | 0.74 | AURKA (0.61) | AURKAAURKBMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | claimed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | claimed |
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | claimed |
| EP-2401267-B1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND THEIR USE IN METHODS | AMBIT BIOSCIENCES CORP (US) | 2014-01-15 | — | — | EP | claimed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | claimed |
| EP-2611502-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | claimed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | claimed |
| WO-2012030918-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | claimed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | claimed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | claimed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | claimed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | AURKA 623/4885AURKB 456/4885MAPT 3086/4885 |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | AURKA 623/4885AURKB 456/4885MAPT 3086/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | AURKA 1009/4885AURKB 1251/4885MAPT 4090/4885 |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | AURKA 623/4885AURKB 456/4885MAPT 3086/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | AURKA 1009/4885AURKB 1251/4885MAPT 4090/4885 |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ADORA2A, ADORA3, ADORA1 | AURKA 3998/4885AURKB 3304/4885MAPT 4254/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | AURKA 1009/4885AURKB 1251/4885MAPT 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.